CSIMarket
 


Acadia Pharmaceuticals Inc   (ACAD)
Other Ticker:  
 

Acadia Pharmaceuticals Inc 's Working Capital Ratio

ACAD's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 2.38 below Acadia Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 252 other companies have achieved higher Working Capital Ratio than Acadia Pharmaceuticals Inc in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 1126 to 1390.

Explain Working Capital Ratio
How much in Current Assets ACAD´s has?
What is the value of ACAD´s Current Liabilities?


ACAD Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 79.81 % 59.7 % 87.54 % 30.77 % 32.14 %
Y / Y Current Assets Change -4.32 % -7.49 % -7.26 % -17.79 % -18.6 %
Working Capital Ratio MRQ 2.38 2.62 2.24 4.04 4.48
ACAD's Total Ranking # 1390 # 1126 # 1636 # 1232 # 1262
Seq. Current Liabilities Change 11.53 % -16.21 % 78.54 % 7.77 % -0.94 %
Seq. Current Assets Change 1.33 % -2.03 % -1 % -2.64 % -2.03 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 253
Healthcare Sector # 509
Overall Market # 1390


Working Capital Ratio Statistics
High Average Low
46.41 11.73 2.24
(Mar 31 2014)   (Mar 31 2023)




Financial Statements
Acadia Pharmaceuticals Inc 's Current Liabilities $ 210 Millions Visit ACAD's Balance sheet
Acadia Pharmaceuticals Inc 's Current Assets $ 499 Millions Visit ACAD's Balance sheet
Source of ACAD's Sales Visit ACAD's Sales by Geography


Cumulative Acadia Pharmaceuticals Inc 's Working Capital Ratio

ACAD's Working Capital Ratio for the trailling 12 Months

ACAD Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 79.81 % 59.7 % 87.54 % 30.77 % 32.14 %
Y / Y Current Assets TTM Growth -4.32 % -7.49 % -7.26 % -17.79 % -18.6 %
Working Capital Ratio TTM 2.68 3.09 3.53 4.39 4.92
Total Ranking TTM # 3921 # 2302 # 622 # 340 # 891
Seq. Current Liabilities TTM Growth 11.53 % -16.21 % 78.54 % 7.77 % -0.94 %
Seq. Current Assets TTM Growth 1.33 % -2.03 % -1 % -2.64 % -2.03 %


On the trailing twelve months basis Due to increase in Current Liabilities in the III Quarter 2023 to $209.60 millions, cumulative Working Capital Ratio decreased to 2.68 below the Acadia Pharmaceuticals Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 488 other companies have achieved higher Working Capital Ratio than Acadia Pharmaceuticals Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 2302 to 3921.

Explain Working Capital Ratio
How much in Current Assets ACAD´s has?
What is the value of ACAD´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 489
Healthcare Sector # 1022
Within the Market # 3921


trailing twelve months Working Capital Ratio Statistics
High Average Low
35.42 11.91 2.68
(Sep. 30, 2014)   (Sep 30 2023)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Coya Therapeutics Inc   6.54 $ 11.823  Millions$ 1.807  Millions
Rhythm Pharmaceuticals inc   6.51 $ 329.201  Millions$ 50.586  Millions
Inflarx N v   6.50 $ 122.605  Millions$ 18.866  Millions
Aadi Bioscience Inc   6.48 $ 132.884  Millions$ 20.517  Millions
Trevena inc   6.41 $ 39.478  Millions$ 6.156  Millions
Ionis Pharmaceuticals Inc  6.39 $ 2,584.650  Millions$ 404.210  Millions
Theravance Biopharma inc   6.37 $ 161.690  Millions$ 25.368  Millions
Pepgen Inc   6.35 $ 133.090  Millions$ 20.955  Millions
Arbutus Biopharma Corp  6.34 $ 141.607  Millions$ 22.324  Millions
Zevra Therapeutics Inc   6.31 $ 137.013  Millions$ 21.714  Millions
Forte Biosciences Inc   6.30 $ 47.102  Millions$ 7.471  Millions
Qilian International Holding Group Limited  6.30 $ 34.513  Millions$ 5.481  Millions
Merus N v   6.29 $ 404.832  Millions$ 64.318  Millions
Pds Biotechnology Corp  6.21 $ 56.838  Millions$ 9.154  Millions
Praxis Precision Medicines Inc   6.15 $ 103.327  Millions$ 16.792  Millions
Citius Pharmaceuticals Inc   5.95 $ 34.408  Millions$ 5.779  Millions
Regeneron Pharmaceuticals Inc   5.86 $ 18,634.800  Millions$ 3,181.300  Millions
Roivant Sciences Ltd   5.84 $ 1,551.627  Millions$ 265.546  Millions
Benitec Biopharma Inc   5.83 $ 26.424  Millions$ 4.534  Millions
Harrow Inc   5.80 $ 110.278  Millions$ 19.029  Millions
Aurinia Pharmaceuticals Inc   5.77 $ 426.469  Millions$ 73.890  Millions
Phibro Animal Health Corporation  5.77 $ 584.424  Millions$ 101.366  Millions
Unity Biotechnology Inc   5.74 $ 49.538  Millions$ 8.633  Millions
Sarepta Therapeutics Inc   5.72 $ 2,450.849  Millions$ 428.249  Millions
Immunogen inc   5.70 $ 766.900  Millions$ 134.660  Millions
Macrogenics Inc   5.68 $ 291.319  Millions$ 51.291  Millions
Dyne Therapeutics Inc   5.67 $ 168.216  Millions$ 29.692  Millions
Alx Oncology Holdings Inc  5.66 $ 199.071  Millions$ 35.142  Millions
Clearside Biomedical Inc   5.63 $ 30.815  Millions$ 5.473  Millions
Kala Bio inc   5.62 $ 57.902  Millions$ 10.301  Millions

Date modified: 2023-11-04T20:24:41+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com